Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

Last updated: October 10, 2018
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Overall Status: Completed

Phase

N/A

Condition

Myopic Macular Degeneration

Treatment

N/A

Clinical Study ID

NCT03115255
XH-17-004
  • Ages < 3
  • All Genders

Study Summary

To determine the serum concentrations of ranibizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Infants with vascularly active ROP

  • intravitreal ranibizumab

Exclusion

Exclusion Criteria:

  • already accepted laser therapy

Study Design

Total Participants: 17
Study Start date:
May 01, 2017
Estimated Completion Date:
June 30, 2018

Study Description

Infants with ROP are studied. They received 0.25 mg or 0.5 mg of intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases) with vascularly active ROP. Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab. The serum concentrations of ranibizumab and VEGF are measured by enzyme-linked immunosorbent assay, and the changes of the serum VEGF levels are determined.

Connect with a study center

  • Xinhua Hospital

    Shanghai, Shanghai 200092
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.